Literature DB >> 24637577

Complete pathological response to neoadjuvant pemetrexed/cisplatin in combination with regional hyperthermia in a patient with sarcomatoid peritoneal mesothelioma.

Stephan Kruger1, Martin K Angele, Simone Reu, Karl Sotlar, Anno Graser, Michael Haas, Markus Albertsmeier, Hans-Joachim Stemmler, Volker Heinemann, Lars H Lindner, Stefan Boeck.   

Abstract

Diffuse malignant peritoneal mesothelioma (DMPM) is a rare disease. Although most patients eligible for surgery undergo cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy, the role of perioperative systemic chemotherapy still remains undefined. Here we report the case of a 52-year-old female patient with advanced sarcomatoid DMPM. After five cycles of systemic pemetrexed and cisplatin, along with two cycles of regional hyperthermia, tumor resection with histomorphological examination showed a complete pathological response. We therefore conclude that there is a subgroup of DMPM patients that might benefit from systemic neoadjuvant chemotherapy with pemetrexed and cisplatin.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24637577     DOI: 10.1097/CAD.0000000000000106

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  1 in total

1.  Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing.

Authors:  Brandon S Sheffield; Anna V Tinker; Yaoqing Shen; Harry Hwang; Hector H Li-Chang; Erin Pleasance; Carolyn Ch'ng; Amy Lum; Julie Lorette; Yarrow J McConnell; Sophie Sun; Steven J M Jones; Allen M Gown; David G Huntsman; David F Schaeffer; Andrew Churg; Stephen Yip; Janessa Laskin; Marco A Marra
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.